Alport's syndrome, Goodpasture's syndrome, and type IV collagen.
about
Characterization of recombinant human prolyl 3-hydroxylase isoenzyme 2, an enzyme modifying the basement membrane collagen IVA sulfilimine bond identified in collagen IVDevelopmental and pathogenic mechanisms of basement membrane assemblyLaminin isoform expression in breast tumors.Stage-specific action of matrix metalloproteinases influences progressive hereditary kidney disease.PodocytesPrinciples of separation: indications and therapeutic targets for plasma exchange.Role of the podocyte (and glomerular endothelium) in building the GBMDevelopments in purification methods for obtaining and evaluation of collagen derived endogenous angioinhibitorsDe novo glomerular diseases after renal transplantationBench-to-bedside review: Pulmonary–renal syndromes – an update for the intensivistOcular features in Alport syndrome: pathogenesis and clinical significanceBromine is an essential trace element for assembly of collagen IV scaffolds in tissue development and architectureA novel COL4A1 gene mutation results in autosomal dominant non-syndromic congenital cataract in a Chinese familyMammalian collagen IVMutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamineZeb1 mutant mice as a model of posterior corneal dystrophyMuscle Tissue Damage Induced by the Venom of Bothrops asper: Identification of Early and Late Pathological Events through Proteomic AnalysisAddition of angiotensin II type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritisAnti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathwaysMolecular mapping of the Goodpasture's epitope for glomerulonephritisThe alpha1.alpha2 network of collagen IV. Reinforced stabilization of the noncollagenous domain-1 by noncovalent forces and the absence of Met-Lys cross-links.Three-dimensional electron microscopy reveals the evolution of glomerular barrier injury.Conformational features of a natural break in the type IV collagen Gly-X-Y repeat.Tetrastatin, the NC1 domain of the α4(IV) collagen chain: a novel potent anti-tumor matrikine.Framingham Heart Study genome-wide association: results for pulmonary function measures.The glomerular transcriptome and a predicted protein-protein interaction network.Crescentic glomerulonephritis and microangiopathic haemolytic anaemia in a patient with established systemic sclerosis.Crucial role of the CB3-region of collagen IV in PARF-induced acute rheumatic fever.A case of fibrillary glomerulonephritis associated with thrombotic microangiopathy and anti-glomerular basement membrane antibody.A meta-analysis of genome-wide data from five European isolates reveals an association of COL22A1, SYT1, and GABRR2 with serum creatinine level.Stem cell therapies benefit Alport syndrome.Effects of Chinese Medicine Tong xinluo on Diabetic Nephropathy via Inhibiting TGF- β 1-Induced Epithelial-to-Mesenchymal Transition.Human nephrosclerosis triggers a hypoxia-related glomerulopathyCOOH-terminal collagen Q (COLQ) mutants causing human deficiency of endplate acetylcholinesterase impair the interaction of ColQ with proteins of the basal lamina.Modeling of human anti-GBM antibody-alpha3(IV)NC1 interactions predicts antigenic cross-linking through contact of both heavy chains with repeating epitopes on alpha3(IV)NC1Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome.A mouse Col4a4 mutation causing Alport glomerulosclerosis with abnormal collagen α3α4α5(IV) trimers.Renal-limited vasculitis with elevated levels of multiple antibodiesHuman biliverdin reductase suppresses Goodpasture antigen-binding protein (GPBP) kinase activity: the reductase regulates tumor necrosis factor-alpha-NF-kappaB-dependent GPBP expression.
P2860
Q24314388-F8EA7A48-D1B3-45C0-9393-39D01305D23EQ24606334-FA3F621A-D296-43BB-84B7-2DBBEEC08839Q24608109-379D2553-F871-4CA7-8425-0B965C102CECQ24810816-A6895066-BAD8-400E-85AC-BCD0CF194502Q25256594-5E2E96CC-7CA9-4086-A3F6-AC4CDB3CC76AQ26766118-F72BC0E0-472E-427F-831E-D75F6442F001Q26830899-9ADAB40E-20A5-4C8E-8CFA-95745E0F98DAQ27003170-DFEE6BC0-0C01-42FB-AB36-BF427A4569E4Q27004391-920C4A01-D50C-4E6B-8581-972B13DEEBBCQ27005877-C1B3BF98-E7AD-48D9-8F89-94AB890DC7E5Q27485164-07413A8D-B9A7-4CD5-99F2-5EA9BB888C90Q28080691-367F8AD8-4756-4478-B617-0B1665D1341AQ28241536-B4BBA622-DE79-425A-9833-E87E42A4B69AQ28245960-B34314B3-8621-4B94-A62D-934A6C5E4CC3Q28265884-2DF1348E-5271-4F54-8527-2025E5EA7058Q28305085-22FF46D6-25BC-4B82-835B-4437A49E919BQ28510771-08A16E03-2C8A-4D0A-A16A-4E60A8A62D6DQ28551136-A566503B-AD87-4F94-8ABE-DA875450180AQ28565493-A7296D7B-16A8-44E8-8CA5-EAD360BDA00AQ30405346-0C9D5C70-83AA-4FFB-848A-B8DBFE7A66E4Q30439840-794A9CE4-D5FC-4F9D-9551-E59148FDEEC0Q30765951-42363E99-32A8-4D40-9766-0706AF07585EQ30820232-379FE6AB-2D69-45F4-BFF9-4D451A1DFE6FQ31036642-509C8FFA-E767-4ABC-8D4A-18346BCFF7D1Q31058993-02D7EA43-8F8B-45BC-BC35-BBC000F0F67BQ33300819-FF19BA06-3F31-45E4-BDEA-5F508175E49EQ33306795-0A36E2DF-545D-49C5-A79D-A6736CB8A7F9Q33397603-861C162C-2877-4F79-A35E-1135124028EBQ33413755-B887FEE8-CFB5-44B9-9A7E-D79A6CA0A242Q33422000-D9C6D09A-2335-4804-AC70-78F77DC22729Q33540002-6E1FBFF3-9780-4BEA-8778-E75ADCCE3772Q33561731-F2CAAA71-4EDA-4698-BEA3-2114CA1E2BF7Q33594088-57B024B3-C816-4848-A5EA-1DB905260EF7Q33597077-A1195088-03E8-4CE3-B27B-3D3D238AA9AAQ33624642-8BCDB211-682F-4521-B617-5855722D9E6EQ33637530-7E91554A-170E-4F4C-B2BB-814307BDF293Q33685580-144F8E95-D09E-480F-9FCB-CF0B6746B175Q33692564-C11D8106-EE95-426A-96E5-71CC2FAF6686Q33710284-5FB4B520-82B9-4D91-A271-4D0B5571A23AQ33799921-E252C5D6-9060-46AA-ACA4-562962DE9E07
P2860
Alport's syndrome, Goodpasture's syndrome, and type IV collagen.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Alport's syndrome, Goodpasture's syndrome, and type IV collagen.
@ast
Alport's syndrome, Goodpasture's syndrome, and type IV collagen.
@en
type
label
Alport's syndrome, Goodpasture's syndrome, and type IV collagen.
@ast
Alport's syndrome, Goodpasture's syndrome, and type IV collagen.
@en
prefLabel
Alport's syndrome, Goodpasture's syndrome, and type IV collagen.
@ast
Alport's syndrome, Goodpasture's syndrome, and type IV collagen.
@en
P2093
P356
P1476
Alport's syndrome, Goodpasture's syndrome, and type IV collagen
@en
P2093
Eric G Neilson
Karl Tryggvason
Munirathinam Sundaramoorthy
P304
P356
10.1056/NEJMRA022296
P407
P577
2003-06-01T00:00:00Z